LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

MRK

109.58

-0.59%↓

LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

MRK

109.58

-0.59%↓

LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

MRK

109.58

-0.59%↓

LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

MRK

109.58

-0.59%↓

LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

MRK

109.58

-0.59%↓

Home・Stock List・Novo Nordisk A-S

Novo Nordisk A-S

Closed

Sector Healthcare

114.93 -0.16

Buy Sell

Overview

Share price change

24h

Current

Min

114.72

Max

115.15

Key metrics
By Trading Economics
Income	-5.4B 20B
Sales	2.7B 68B
P/E Sector Avg	49.94 113.916
EPS	4.49
Profit margin	29.459
EBITDA	-1.2B 36B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+34.86 upside

Market Stats
By TradingEconomics
Market Cap	-6.4B 394B
Previous open	115.09
Previous close	114.93

News Sentiment

By Acuity

64%

36%

332 / 366 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

115.03 / 119.15 Support & Resistance

Novo Nordisk A-S Chart

Past performance is not a reliable indicator of future results.

Related News

23 Sept 2024, 19:26 UTC

Major Market Movers

Skye Bioscience Shares Gain After Highlighting Safety of In-Development Obesity Treatment

4 Oct 2024, 12:01 UTC

Top News

As Weight-Loss Drugs Battle, Upstart Viking -2-

4 Oct 2024, 12:01 UTC

Top News

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

3 Oct 2024, 14:45 UTC

Top News

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 Oct 2024, 13:12 UTC

Top News

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 Oct 2024, 12:51 UTC

Market Talk

Novo Nordisk's Weight-Loss Jab Trial Will Be Defining -- Market Talk

2 Oct 2024, 13:48 UTC

Earnings

Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com

2 Oct 2024, 12:28 UTC

Market Talk

Novo Nordisk Shares Unlikely to Move Ahead of New Drug Data -- Market Talk

2 Oct 2024, 09:00 UTC

Market Talk

Novo Nordisk's New Weight-Loss Jab Could Support Co Into 2030s -- Market Talk

26 Sept 2024, 13:15 UTC

Market Talk

Novo Nordisk's Share Price Looks Capped Ahead of New Drug Data -- Market Talk

26 Sept 2024, 11:51 UTC

Market Talk

Novo Nordisk Senate Hearing Removes a Share Overhang -- Market Talk

23 Sept 2024, 10:37 UTC

Top News

Fed Uncertainty Is History. Now Markets Need to Brace for Election Volatility. -- Barrons.com

23 Sept 2024, 10:37 UTC

Top News

Fed Uncertainty Is History. Now Markets Need to -2-

20 Sept 2024, 16:30 UTC

Market Talk

'Knee-Jerk' Corbus Selloff Seen as Buying Opportunity -- Market Talk

20 Sept 2024, 13:55 UTC

Top News

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

20 Sept 2024, 12:46 UTC

Top News

Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

20 Sept 2024, 09:30 UTC

Top News

The Price War in Weight-Loss Drugs Is Here -- WSJ

12 Sept 2024, 13:00 UTC

Top News

Senators Target Influencers, Telehealth Firms for Misleading Weight-Loss and Other Drug Promotion -- WSJ

12 Sept 2024, 11:45 UTC

Market Talk

Earnings

Novo Nordisk's Obesity Pill Data Confirm Investor Optimism -- Market Talk

12 Sept 2024, 10:30 UTC

Market Talk

Earnings

Novo Nordisk's Amycretin Obesity Pill Slightly Disappoints on Safety -- Market Talk

11 Sept 2024, 12:08 UTC

Top News

Novo Nordisk Stock Rises After Study Finds Obesity Drug Safe For Kids -- Barrons.com

9 Sept 2024, 07:56 UTC

Market Talk

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

3 Sept 2024, 11:09 UTC

Top News

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com

27 Aug 2024, 05:30 UTC

Top News

Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com

14 Aug 2024, 12:01 UTC

Market Talk

Earnings

Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk

9 Aug 2024, 11:30 UTC

Top News

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ

9 Aug 2024, 07:30 UTC

Market Talk

Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk

8 Aug 2024, 15:44 UTC

Top News

Earnings

Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ

8 Aug 2024, 11:36 UTC

Market Talk

Earnings

Novo Nordisk's Share-Price Weakness Provides an Opportunity -- Market Talk

8 Aug 2024, 07:16 UTC

Market Talk

Earnings

Novo Nordisk's Share-Price Drop Provides Buying Opportunity -- Market Talk

Peer Comparison

Price change

Novo Nordisk A-S Forecast

Price Target

By TipRanks

34.86% upside

12 Months Forecast

Average 155.25 USD 34.86%

High 160 USD

Low 146 USD

Based on 8 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Novo Nordisk A-S - Dist in the past 3 months.

Technical Score

By Trading Central

115.03 / 119.15Support & Resistance

All events are bearish.

Sentiment

By Acuity

332 / 366 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

About Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.